View in EDS PDF Full Text

Controversial Role of the Immune Checkpoint OX40L Expression on Platelets in Breast Cancer Progression.

Saved in:
Bibliographic Details
Title: Controversial Role of the Immune Checkpoint OX40L Expression on Platelets in Breast Cancer Progression.
Authors: Rittig SM; Department of Hematology, Oncology and Cancer Immunology, Charité - Universitaetsmedizin Berlin, Corporate Member of Freie Universitaet Berlin and Humboldt-Universitaet zu Berlin, Berlin, Germany.; Berlin Institute of Health at Charité - Universitaetsmedizin Berlin, BIH Biomedical Innovation Academy, BIH Charité (Junior) (Digital) Clinician Scientist Program, Berlin, Germany., Lutz MS; Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Department of Internal Medicine, University Hospital Tuebingen, Tuebingen, Germany.; Cluster of Excellence iFIT (EXC 2180) 'Image-Guided and Functionally Instructed Tumor Therapies' , University of Tuebingen, Tuebingen, Germany., Clar KL; Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Department of Internal Medicine, University Hospital Tuebingen, Tuebingen, Germany.; Cluster of Excellence iFIT (EXC 2180) 'Image-Guided and Functionally Instructed Tumor Therapies' , University of Tuebingen, Tuebingen, Germany., Zhou Y; Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Department of Internal Medicine, University Hospital Tuebingen, Tuebingen, Germany.; Cluster of Excellence iFIT (EXC 2180) 'Image-Guided and Functionally Instructed Tumor Therapies' , University of Tuebingen, Tuebingen, Germany., Kropp KN; Department of Hematology, Medical Oncology and Pneumology, University Medical Center of Mainz, Mainz, Germany., Koch A; Department of Obstetrics and Gynecology, University Hospital Tuebingen, Tuebingen, Germany., Hartkopf AD; Department of Obstetrics and Gynecology, University Hospital Tuebingen, Tuebingen, Germany.; Department of Gynecology and Obstetrics, University Hospital of Ulm, Ulm, Germany., Hinterleitner M; Cluster of Excellence iFIT (EXC 2180) 'Image-Guided and Functionally Instructed Tumor Therapies' , University of Tuebingen, Tuebingen, Germany.; Department of Medical Oncology and Pneumology (Internal Medicine VIII), University Hospital Tuebingen, Tuebingen, Germany., Zender L; Cluster of Excellence iFIT (EXC 2180) 'Image-Guided and Functionally Instructed Tumor Therapies' , University of Tuebingen, Tuebingen, Germany.; Department of Medical Oncology and Pneumology (Internal Medicine VIII), University Hospital Tuebingen, Tuebingen, Germany.; German Cancer Research Consortium (DKTK), Partner Site Tuebingen, German Cancer Research Center (DKFZ), Heidelberg, Germany., Salih HR; Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Department of Internal Medicine, University Hospital Tuebingen, Tuebingen, Germany.; Cluster of Excellence iFIT (EXC 2180) 'Image-Guided and Functionally Instructed Tumor Therapies' , University of Tuebingen, Tuebingen, Germany., Maurer S; Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Department of Internal Medicine, University Hospital Tuebingen, Tuebingen, Germany.; Cluster of Excellence iFIT (EXC 2180) 'Image-Guided and Functionally Instructed Tumor Therapies' , University of Tuebingen, Tuebingen, Germany.; Precision Immunology Institute, Department of Oncological Sciences, and The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, United States., Hinterleitner C; Cluster of Excellence iFIT (EXC 2180) 'Image-Guided and Functionally Instructed Tumor Therapies' , University of Tuebingen, Tuebingen, Germany.; Department of Medical Oncology and Pneumology (Internal Medicine VIII), University Hospital Tuebingen, Tuebingen, Germany.; Department of Cancer Biology and Genetics, Memorial Sloan Kettering Cancer Center, New York, NY, United States.
Source: Frontiers in oncology [Front Oncol] 2022 Jul 08; Vol. 12, pp. 917834. Date of Electronic Publication: 2022 Jul 08 (Print Publication: 2022).
Publication Type: Journal Article
Journal Info: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
FullText Links:
  – Type: pdflink
Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 35875148
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Controversial Role of the Immune Checkpoint OX40L Expression on Platelets in Breast Cancer Progression.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Rittig+SM%22">Rittig SM</searchLink>; Department of Hematology, Oncology and Cancer Immunology, Charité - Universitaetsmedizin Berlin, Corporate Member of Freie Universitaet Berlin and Humboldt-Universitaet zu Berlin, Berlin, Germany.; Berlin Institute of Health at Charité - Universitaetsmedizin Berlin, BIH Biomedical Innovation Academy, BIH Charité (Junior) (Digital) Clinician Scientist Program, Berlin, Germany.<br /><searchLink fieldCode="AU" term="%22Lutz+MS%22">Lutz MS</searchLink>; Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Department of Internal Medicine, University Hospital Tuebingen, Tuebingen, Germany.; Cluster of Excellence iFIT (EXC 2180) 'Image-Guided and Functionally Instructed Tumor Therapies' , University of Tuebingen, Tuebingen, Germany.<br /><searchLink fieldCode="AU" term="%22Clar+KL%22">Clar KL</searchLink>; Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Department of Internal Medicine, University Hospital Tuebingen, Tuebingen, Germany.; Cluster of Excellence iFIT (EXC 2180) 'Image-Guided and Functionally Instructed Tumor Therapies' , University of Tuebingen, Tuebingen, Germany.<br /><searchLink fieldCode="AU" term="%22Zhou+Y%22">Zhou Y</searchLink>; Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Department of Internal Medicine, University Hospital Tuebingen, Tuebingen, Germany.; Cluster of Excellence iFIT (EXC 2180) 'Image-Guided and Functionally Instructed Tumor Therapies' , University of Tuebingen, Tuebingen, Germany.<br /><searchLink fieldCode="AU" term="%22Kropp+KN%22">Kropp KN</searchLink>; Department of Hematology, Medical Oncology and Pneumology, University Medical Center of Mainz, Mainz, Germany.<br /><searchLink fieldCode="AU" term="%22Koch+A%22">Koch A</searchLink>; Department of Obstetrics and Gynecology, University Hospital Tuebingen, Tuebingen, Germany.<br /><searchLink fieldCode="AU" term="%22Hartkopf+AD%22">Hartkopf AD</searchLink>; Department of Obstetrics and Gynecology, University Hospital Tuebingen, Tuebingen, Germany.; Department of Gynecology and Obstetrics, University Hospital of Ulm, Ulm, Germany.<br /><searchLink fieldCode="AU" term="%22Hinterleitner+M%22">Hinterleitner M</searchLink>; Cluster of Excellence iFIT (EXC 2180) 'Image-Guided and Functionally Instructed Tumor Therapies' , University of Tuebingen, Tuebingen, Germany.; Department of Medical Oncology and Pneumology (Internal Medicine VIII), University Hospital Tuebingen, Tuebingen, Germany.<br /><searchLink fieldCode="AU" term="%22Zender+L%22">Zender L</searchLink>; Cluster of Excellence iFIT (EXC 2180) 'Image-Guided and Functionally Instructed Tumor Therapies' , University of Tuebingen, Tuebingen, Germany.; Department of Medical Oncology and Pneumology (Internal Medicine VIII), University Hospital Tuebingen, Tuebingen, Germany.; German Cancer Research Consortium (DKTK), Partner Site Tuebingen, German Cancer Research Center (DKFZ), Heidelberg, Germany.<br /><searchLink fieldCode="AU" term="%22Salih+HR%22">Salih HR</searchLink>; Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Department of Internal Medicine, University Hospital Tuebingen, Tuebingen, Germany.; Cluster of Excellence iFIT (EXC 2180) 'Image-Guided and Functionally Instructed Tumor Therapies' , University of Tuebingen, Tuebingen, Germany.<br /><searchLink fieldCode="AU" term="%22Maurer+S%22">Maurer S</searchLink>; Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Department of Internal Medicine, University Hospital Tuebingen, Tuebingen, Germany.; Cluster of Excellence iFIT (EXC 2180) 'Image-Guided and Functionally Instructed Tumor Therapies' , University of Tuebingen, Tuebingen, Germany.; Precision Immunology Institute, Department of Oncological Sciences, and The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, United States.<br /><searchLink fieldCode="AU" term="%22Hinterleitner+C%22">Hinterleitner C</searchLink>; Cluster of Excellence iFIT (EXC 2180) 'Image-Guided and Functionally Instructed Tumor Therapies' , University of Tuebingen, Tuebingen, Germany.; Department of Medical Oncology and Pneumology (Internal Medicine VIII), University Hospital Tuebingen, Tuebingen, Germany.; Department of Cancer Biology and Genetics, Memorial Sloan Kettering Cancer Center, New York, NY, United States.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101568867%22">Frontiers in oncology</searchLink> [Front Oncol] 2022 Jul 08; Vol. 12, pp. 917834. <i>Date of Electronic Publication: </i>2022 Jul 08 (<i>Print Publication: </i>2022).
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Frontiers+Research+Foundation]%22">Frontiers Research Foundation] </searchLink><i>Country of Publication: </i>Switzerland <i>NLM ID: </i>101568867 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Print <i>ISSN: </i>2234-943X (Print) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%222234943X%22">2234943X </searchLink><i>NLM ISO Abbreviation: </i>Front Oncol <i>Subsets: </i>PubMed not MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=35875148
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.3389/fonc.2022.917834
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 917834
    Titles:
      – TitleFull: Controversial Role of the Immune Checkpoint OX40L Expression on Platelets in Breast Cancer Progression.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Rittig SM
      – PersonEntity:
          Name:
            NameFull: Lutz MS
      – PersonEntity:
          Name:
            NameFull: Clar KL
      – PersonEntity:
          Name:
            NameFull: Zhou Y
      – PersonEntity:
          Name:
            NameFull: Kropp KN
      – PersonEntity:
          Name:
            NameFull: Koch A
      – PersonEntity:
          Name:
            NameFull: Hartkopf AD
      – PersonEntity:
          Name:
            NameFull: Hinterleitner M
      – PersonEntity:
          Name:
            NameFull: Zender L
      – PersonEntity:
          Name:
            NameFull: Salih HR
      – PersonEntity:
          Name:
            NameFull: Maurer S
      – PersonEntity:
          Name:
            NameFull: Hinterleitner C
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 08
              M: 07
              Text: 2022 Jul 08
              Type: published
              Y: 2022
          Identifiers:
            – Type: issn-print
              Value: 2234-943X
          Numbering:
            – Type: volume
              Value: 12
          Titles:
            – TitleFull: Frontiers in oncology
              Type: main
ResultId 1